2005
Erythropoietin and Cancer
Search citation statements
Paper Sections
Select...
26
2
0
0
Citation Types
0
5
0
0
Year Published
2005
2019
Publication Types
Select...
25
2
1
Relationship
0
28
Authors
Journals
Cited by 28 publications
(5 citation statements)
References 2 publications
0
5
0
0
“…Yet, further investigative studies for WISP1 are clearly indicated. Similar to other growth promoting agents [87–90], WISP1 has been associated with tumorigenesis in esophageal carcinoma [91], in chondrosarcoma [92], and in colorectal cancer [93]. Future work that can further elucidate pathways governed by WISP1 that oversee cellular survival and growth will prove to be invaluable in determining effective and safe applications for WISP1 not only in neurodegenerative disorders, but also in diseases involving other systems of the body.…”
Section: Discussion
mentioning
confidence: 99%
“…Yet, further investigative studies for WISP1 are clearly indicated. Similar to other growth promoting agents [87–90], WISP1 has been associated with tumorigenesis in esophageal carcinoma [91], in chondrosarcoma [92], and in colorectal cancer [93]. Future work that can further elucidate pathways governed by WISP1 that oversee cellular survival and growth will prove to be invaluable in determining effective and safe applications for WISP1 not only in neurodegenerative disorders, but also in diseases involving other systems of the body.…”
Section: Discussion
mentioning
confidence: 99%
“…Novel therapeutic strategies such as EPO may offer great promise to develop new treatments for disease of the nervous system [14], [15], [26], [27], [52], [86], [87]. However, EPO is not without detrimental effects such as during hypertension [88], [89], vascular disease [90], [91], [92], and cancer progression [93], [94], [95], [96]. Therefore it is crucial to identify and target the cellular mechanisms of EPO that can provide robust cytoprotection without detrimental consequences.…”
Section: Discussion
mentioning
confidence: 99%
“…The FDA has issued a public health advisory for erythropoiesis-stimulating agents (ESAs) that includes EPO, notifying physicians and patients of complications with ESAs that include increased rate of tumor growth and death in patients with cancer as well as blood clots, strokes, heart failure, and heart attacks in patients with chronic kidney failure when ESAs are administered to maintain hemoglobin levels greater than 12 g/dL. EPO, as a known growth factor, has been associated with tumorigenesis that may complicate administration of EPO in cancer patients suffering from anemia [235–237]. EPO treatment also may require careful modulation and in some cases, more is not better.…”
Section: Conclusion and Future Perspectives
mentioning
confidence: 99%
